Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.

<h4>Objective</h4>To characterize nationwide utilization patterns of migraine pharmacotherapy before, during, and after pregnancy in women with triptan use.<h4>Methods</h4>Population-based data were obtained by linking the Medical Birth Registry of Norway and the Norwegian Pr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fatima Tauqeer, Mollie Wood, Sarah Hjorth, Angela Lupattelli, Hedvig Nordeng
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/fa7e26a8db09438bb141ac5c62683302
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fa7e26a8db09438bb141ac5c62683302
record_format	dspace
spelling	oai:doaj.org-article:fa7e26a8db09438bb141ac5c626833022021-12-02T20:17:39ZPerinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.1932-620310.1371/journal.pone.0256214https://doaj.org/article/fa7e26a8db09438bb141ac5c626833022021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0256214https://doaj.org/toc/1932-6203<h4>Objective</h4>To characterize nationwide utilization patterns of migraine pharmacotherapy before, during, and after pregnancy in women with triptan use.<h4>Methods</h4>Population-based data were obtained by linking the Medical Birth Registry of Norway and the Norwegian Prescription Database from 2006 to 2017. We included 22,940 pregnancies among 19,669 women with at least one filled triptan prescription, a proxy for migraine, in the year before pregnancy or during pregnancy. The population was classified into four groups: i) continuers; ii) discontinuers; iii) initiators, and vi) post-partum re-initiators. Participant characteristics and prescription fills for other drugs such as analgesics, antinauseants, and preventive drugs among the groups were examined, along with an array of triptan utilization parameters.<h4>Results</h4>In total, 20.0% of the women were classified as triptan continuers, 54.1% as discontinuers, 8.0% as initiators, and 17.6% as re-initiators. Extended use of triptans (≥15 daily drug doses/month) occurred among 6.9% of the continuers in the first trimester. The top 10% of triptan continuers and initiators accounted for 41% (95% CI: 39.2% - 42.5%) and 33% (95% CI: 30.3% - 35.8%) of the triptan volume, respectively. Triptan continuers and initiators had similar patterns of acute co-medication during pregnancy, but use of preventive drugs was more common among the continuers before, during, and after pregnancy.<h4>Conclusion</h4>Among women using triptans before and during pregnancy, one in four continued triptan treatment during pregnancy, and extended triptan use was relatively low. Triptan discontinuation during and in the year after pregnancy was common. Use of other acute migraine treatments was higher among both continuers and initiators of triptans. Women using preventive migraine treatment were most commonly triptan continuers and re-initiators after pregnancy. Prescribing to and counseling of women with migraine should be tailored to the condition severity and their information needs to promote optimal migraine management in pregnancy.Fatima TauqeerMollie WoodSarah HjorthAngela LupattelliHedvig NordengPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 8, p e0256214 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Fatima Tauqeer Mollie Wood Sarah Hjorth Angela Lupattelli Hedvig Nordeng Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
description	<h4>Objective</h4>To characterize nationwide utilization patterns of migraine pharmacotherapy before, during, and after pregnancy in women with triptan use.<h4>Methods</h4>Population-based data were obtained by linking the Medical Birth Registry of Norway and the Norwegian Prescription Database from 2006 to 2017. We included 22,940 pregnancies among 19,669 women with at least one filled triptan prescription, a proxy for migraine, in the year before pregnancy or during pregnancy. The population was classified into four groups: i) continuers; ii) discontinuers; iii) initiators, and vi) post-partum re-initiators. Participant characteristics and prescription fills for other drugs such as analgesics, antinauseants, and preventive drugs among the groups were examined, along with an array of triptan utilization parameters.<h4>Results</h4>In total, 20.0% of the women were classified as triptan continuers, 54.1% as discontinuers, 8.0% as initiators, and 17.6% as re-initiators. Extended use of triptans (≥15 daily drug doses/month) occurred among 6.9% of the continuers in the first trimester. The top 10% of triptan continuers and initiators accounted for 41% (95% CI: 39.2% - 42.5%) and 33% (95% CI: 30.3% - 35.8%) of the triptan volume, respectively. Triptan continuers and initiators had similar patterns of acute co-medication during pregnancy, but use of preventive drugs was more common among the continuers before, during, and after pregnancy.<h4>Conclusion</h4>Among women using triptans before and during pregnancy, one in four continued triptan treatment during pregnancy, and extended triptan use was relatively low. Triptan discontinuation during and in the year after pregnancy was common. Use of other acute migraine treatments was higher among both continuers and initiators of triptans. Women using preventive migraine treatment were most commonly triptan continuers and re-initiators after pregnancy. Prescribing to and counseling of women with migraine should be tailored to the condition severity and their information needs to promote optimal migraine management in pregnancy.
format	article
author	Fatima Tauqeer Mollie Wood Sarah Hjorth Angela Lupattelli Hedvig Nordeng
author_facet	Fatima Tauqeer Mollie Wood Sarah Hjorth Angela Lupattelli Hedvig Nordeng
author_sort	Fatima Tauqeer
title	Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
title_short	Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
title_full	Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
title_fullStr	Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
title_full_unstemmed	Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.
title_sort	perinatal use of triptans and other drugs for migraine-a nationwide drug utilization study.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/fa7e26a8db09438bb141ac5c62683302
work_keys_str_mv	AT fatimatauqeer perinataluseoftriptansandotherdrugsformigraineanationwidedrugutilizationstudy AT molliewood perinataluseoftriptansandotherdrugsformigraineanationwidedrugutilizationstudy AT sarahhjorth perinataluseoftriptansandotherdrugsformigraineanationwidedrugutilizationstudy AT angelalupattelli perinataluseoftriptansandotherdrugsformigraineanationwidedrugutilizationstudy AT hedvignordeng perinataluseoftriptansandotherdrugsformigraineanationwidedrugutilizationstudy
_version_	1718374383735537664

Perinatal use of triptans and other drugs for migraine-A nationwide drug utilization study.

Ejemplares similares